User login
Quotient Limited to Participate in the Jefferies Virtual Healthcare Conference
JERSEY, Channel Islands, May 27, 2020 (GLOBE NEWSWIRE) -- Quotient Limited (NASDAQ:QTNT), a commercial-stage diagnostics company, today announced the Company will present at the Jefferies Virtual Healthcare Conference on Tuesday, June 2, 2020 at 9:00 a.m. ET.
Quotient Limited to Report Fiscal Fourth Quarter and Full Year 2020 Financial Results and Host Conference Call
JERSEY, Channel Islands, May 26, 2020 (GLOBE NEWSWIRE) – Quotient Limited (NASDAQ:QTNT), a commercial-stage diagnostics company, today announced that financial results for its fiscal fourth quarter and full year ended March 31, 2020 will be released before market open on Tuesday, June 9, 2020.
Quotient Limited and hVIVO Announce Partnership to Support Wide-Spread COVID-19 Antibody Testing in the UK
JERSEY, Channel Islands, May 11, 2020 (GLOBE NEWSWIRE) -- Quotient Limited (NASDAQ:QTNT), a commercial-stage diagnostics company, headquartered in Eysins, Switzerland, and hVIVO, part of Open Orphan plc (LONDON:ORPH), today announced that the MosaiQ™ by Quotient system and MosaiQ COVID-19 Antibody…
Quotient Limited Announces CE Mark for its SARS-CoV-2 (COVID-19) Antibody Microarray
JERSEY, Channel Islands, 1 May, 2020 (GLOBE NEWSWIRE) -- Quotient Limited (NASDAQ:QTNT), a commercial-stage diagnostics company (the Company), headquartered in Eysins, Switzerland, today announced that it has completed the process for declaring conformity to the essential requirements of the In…
Quotient Limited Announces SARS-CoV-2 (COVID-19) Antibody Test Final Performance Data
JERSEY, Channel Islands, April 27, 2020 (GLOBE NEWSWIRE) -- Quotient Limited (NASDAQ:QTNT), a commercial-stage diagnostics company (the Company), headquartered in Eysins, Switzerland, today reported very strong final study performance data for its SARS-CoV-2 antibody test. The Company expects to…
Quotient Limited Announces the Completion of the SARS-CoV-2 Antibody Test Development
JERSEY, Channel Islands, April 06, 2020 (GLOBE NEWSWIRE) -- Quotient Limited (NASDAQ:QTNT), a commercial-stage diagnostics company (the Company), headquartered in Eysins, Switzerland, today announced the completion of the development phase of a microarray based SARS-CoV-2 (COVID-19) antibody test…
Quotient Limited Reports Concordance Data from Extended Serological Disease Screening Benchmark Study
Quotient Limited Announces CE Mark Approval for Initial Serological Disease Screening Microarray